Long Term Outcome of Intravitreal Ranibizumab for ROP

Ameera Gamal Abdelhameed140 enrolled

Overview

premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year were examined for refractive state and biometry

Medical records were collected in each group for birth history data, including gestational age (GA), birth weight (BW), and postmenstrual age (PMA) at time of intravitreal injection. The zone and stage of ROP were also recorded. All patients were evaluated for refractive errors and cycloplegic refraction was performed using a handheld auto keratorefractometer (Righton Retinomax K-plus2), and confirmed by retinoscopy examination. Refractive errors were calculated as spherical equivalent and astigmatism in cylinder. The average corneal radius of curvature was measured by handheld auto kerato-refractometer (Righton Retinomax K-plus2). The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek)

Study Type

OBSERVATIONAL

Enrollment

140

Conditions

Retinopathy of Prematurity

Interventions

cycloplegic refractionOTHER

Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder. The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * premature infants who had a history of intravitreal injection of (Ranibizumab) not less than one year * Three control groups with age and sex matched were included for comparison. First group included premature infants who had ROP that regressed spontaneously without intervention. Second group was corresponded to premature infants who were diagnosed to have normal retinal vasculature from the first examination after birth. The third group belonged to full term babies Exclusion Criteria: * Premature infants who received intravitreal injection of (Ranibizumab) less than one year or had any ocular pathology

Locations (1)

Mansoura University

Al Mansurah, Dakahlia Governorate, Egypt

Outcomes

Primary Outcomes

cycloplegic refraction

Time frame: 1 year after injection

biometry

The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek). Examination under sedation was performed for uncooperative children.

Time frame: 1 year after injection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.